Pharmacotherapy of Neurodegenerative Diseases
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.contributor.author | Adem, Muna Abdu | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Drimba, László | |
| dc.contributor.opponent | Szentmiklósi, József András | |
| dc.contributor.opponentdept | Kenézy Kórház Aneszteziológiai és Intenziv Therápiás Osztály | hu_HU |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.date.accessioned | 2022-08-24T13:59:12Z | |
| dc.date.available | 2022-08-24T13:59:12Z | |
| dc.date.created | 2022-05-22 | |
| dc.description.abstract | Amyotrophic Lateral Sclerosis (ALS) is a fatal idiopathic neurodegenerative disease that is characterized by degeneration of both upper and lower motor neurons. ALS currently only has 2 drugs approved as disease modyfying, whereas the rest of the therapy is palliative. Huntingtons Disease (HD) is a neurodegenerative disorder that impairs motor and cognitive functions. Advances in understanding the basic pathological mechanism(s) of HD has yet to translate into an effective disease-modifying therapy | hu_HU |
| dc.description.corrector | hbk | |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 37 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/336760 | |
| dc.language.iso | en | hu_HU |
| dc.subject | Neurodegenerative diseases | hu_HU |
| dc.subject | ALS | hu_HU |
| dc.subject | Amyotrophic Lateral Sclerosis | hu_HU |
| dc.subject | Huntingtons Disease | hu_HU |
| dc.subject | HD | hu_HU |
| dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
| dc.title | Pharmacotherapy of Neurodegenerative Diseases | hu_HU |